Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.20
(
0.68%
)
Bitcoin
77,025.31
(
-0.49%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 109575

Thursday, 08/11/2011 8:51:12 AM

Thursday, August 11, 2011 8:51:12 AM

Post# of 257580
Portola will present additional preclinical data for FXa antidote at ESC:

http://finance.yahoo.com/news/Portola-Pharmaceuticals-iw-4201779648.html?x=0&.v=1

Today’s PR contends that PRT064445 can reverse the effect of direct FXa inhibitors, a class that includes Xarelto and Eliquis (and Portola's own Betrixaban), but not Pradaxa.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today